N01.7
Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis
Clinical Classification Guidelines
Inclusion Terms
- Rapidly progressive nephritic syndrome with extracapillary glomerulonephritis
Medical Intelligence & Overview
Rapidly Progressive Nephritic Syndrome (RPGN), also known as crescentic glomerulonephritis, is a severe kidney condition characterized by a swift decline in kidney function. When associated with diffuse crescent formation in the glomeruli, it leads to significant damage to the filtering units of the kidney, often resulting in kidney failure if not promptly diagnosed and treated. This condition is identified by the ICD-10 code N01.7 and requires urgent medical attention to manage the symptoms and underlying causes effectively.
Causes & Symptoms
Clinical Causes: Autoimmune diseases such as Goodpasture’s syndrome or systemic lupus erythematosus Infections causing immune response, including certain bacterial or viral infections Drug reactions or exposure to harmful toxins Vasculitis, which involves inflammation of blood vessels affecting kidney tissue Idiopathic causes where no specific reason is identified
Key Symptoms: Rapid decline in kidney function, leading to fluid retention and swelling Blood in the urine or smoky, dark appearance of urine High blood pressure (hypertension) Fatigue and weakness due to toxin buildup Nausea, vomiting, or loss of appetite Decreased urine output or oliguria Edema, especially in the legs, ankles, or around the eyes Fever and malaise in some cases
Diagnostic & Treatment
Diagnosis Path: Diagnosis of this condition involves a combination of medical history, physical examination, and several laboratory tests. These include blood tests to assess kidney function (such as serum creatinine and blood urea nitrogen), urinalysis to detect blood and protein in urine, and imaging studies like ultrasound. A definitive diagnosis often requires a kidney biopsy, where tissue samples are examined under a microscope to identify crescent formation and immune deposits, confirming diffuse crescentic glomerulonephritis.
Treatment Protocols: Treatment strategies aim to suppress the immune response, control blood pressure, and prevent further kidney damage. Common approaches include corticosteroids and immunosuppressive medications to reduce inflammation. Plasmapheresis (plasma exchange) may be used in cases with autoimmune components like Goodpasture’s syndrome. Managing blood pressure with antihypertensive drugs and addressing complications such as fluid overload or electrolyte imbalance are also vital. In severe cases where kidney function cannot be preserved, dialysis may become necessary, and in some instances, kidney transplantation might be considered.
Clinical Advice & FAQs
Billing Guidance
Is N01.7 a billable ICD-10 code?
Yes, N01.7 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report N01.7?
Clinical documentation must specify the nature of Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference